2
Clinical Trials associated with TAKC-02An exploratory study of TAKC-02 in male patients with moderate bronchial asthma
Start Date08 Mar 2023 |
Sponsor / Collaborator- |
The Safety and Pharmacokinetics Study of TAKC-02 Inhalation Solution in Healthy Adult Males.
MEX3B is an RNA-binding protein that is conserved in many animal species and has wide range of biological function. The MEX3B protein is deeply involved in the expression of various cytokines associated with the onset and exacerbation of several diseases such as inflammatory diseases, metabolic diseases, and malignant tumors. TAKC-02 is a nucleic acid medicine, antisense oligonucleotide, inhibits the MEX3B synthesis expected to have potential as new medication.
This plans to evaluate the safety profile of the inhalation solution in order to develop TAKC-02 for severe asthma.
The study is a double-blind, randomized, placebo-controlled Phase I study. The primary objective of the study is to assess the safety and tolerability of single and multiple inhaled doses of TAKC-02 in healthy male subjects. The study is a Single Ascending Dose (Step 1) followed by a Multiple Comparative Dose (Step 2).
100 Clinical Results associated with TAKC-02
100 Translational Medicine associated with TAKC-02
100 Patents (Medical) associated with TAKC-02
100 Deals associated with TAKC-02